“HiberGene is a company that had hit a classic speedbump where it had developed great products but was not seeing the revenues,” CEO David Corr told The Currency last March. With 13 products in the company’s armoury, including a Covid 19/flu combo test, Corr was optimistic that the experienced executive team behind the medical diagnostics firm could turn the business around. In the wings were investors Des and Brendan O’Farrell, brothers from Meath who had made it big in the US, by setting up successful American diagnostic firms Empirical Bioscience and DCN Dx and now wanted to invest in Ireland. The…

Want to continue reading?

Join today with an Annual membership and get full access to The Currency for just €200 (68c per day) or try monthly membership for just €5 for your first month.

Subscribe

Cancel at any time.

Are you already a member? .